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Thrombocytopenia in renal failure. 0. Aboo and Y.K. Seedat, Renal
Unit, Department of Medicine, University of Natal and King Edward
VIII Hospital, Durban, Natal, Republic of South Africa. A retrospec-
tive study over a three year period looking at predialysis platelet levels,
in particular, thrombocytopenia, was done. Seventy-five patients with
acute renal failure (ARF) and 75 patients with chronic renal failure
(CRF) treated at King Edward VIII Hospital were randomly chosen.
Platelet counts were performed on a coulter counter (S + 2) and counts
of less than 150,000 x 10' 1 were considered as thrombocytopenia. Of
the 75 CRF patients 47 were males. Eleven (14.7%) were thrombocy-
topenic with a mean platelet count of 118.3 x 10' 1 and a range of
83—146 X 10' 1. The mean creatinine level was 1510 tg/Iiter. The
remaining non-thrombocytopenic patients had a mean platelet count of
268 x 10' 1 and a mean creatinine of 1080 gIliter. Of the ARF patients
39 were males. Twenty-two (29.3%) had thrombocytopenia with a mean
platelet count of 98 x 10' 1 and a range of 22—147 X 10' 1. The mean
creatinine level was 819 .tg/1iter. The remaining non-thrombocytopenic
patients had a mean platelet count of 319 x 10' 1 and a mean creatinine
of 1020 gfliter. In CRF patients no correlation was found between
thrombocytopenia and or the disease process. Creatinine levels appear
to be higher in the thrombocytopenic group than the non-thrombocy-
topenic group. In the ARF group of patients, females had a higher
frequency of thrombocytopenia than males. Obstetrical and gynecolog-
ical causes and herbal ingestion were the two major underlying etiolo-
gies in the thrombocytopenic group. Thrombocytopenia appears to be a
common presenting feature in ARF as opposed to CRF, and this may be
accounted for by the underlying etiologies in ARF.
Kidney biopsy results in Bloemfontein academic hospitals. HG. Vii-
joen, and B.P. Botha, Department of Internal Medicine, Division of
Nephrology, UOFS, Bloemfontein, South Africa. Various differences
in renal diseases in the White and Black populations have been
described. More Black than White patients with renal diseases are
treated in the Bloemfontein renal units. The Black patients are mainly
referred from rural areas. The aim of the study was to look at the renal
biopsies performed in the division of Nephrology and to quantify
differences between the various patient groups. A retrospective study
of all kidney biopsies performed since 1989 was done. Records of all
clinical and laboratory results were evaluated. Only patients with
complete clinical records were included in the study. Biopsy results of
206 patients were included in the study. All biopsies were performed
with ultrasound guidance by the personnel of the renal units. Sixty-
seven biopsies were performed on White patients and 139 on Blacks.
Only three patients developed complications (1.5%), and none required
surgery. Glomerulonephritis was the most common diagnosis in both
groups. Mesangiocapillary glomerulonephritis was the most common
diagnosis in Blacks, and membranous glomerulonephritis the most
common in whites males. IGA nephropathy was found only in White
males. Minimal change renal disease was significantly more common in
males. Differences in renal diseases between Black and White patients
and between the male and female patients were found. Ultrasound
guided biopsies are very safe if the necessary precautions are taken.
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Altered erythrocyte charge in adult onset nephrotic syndrome. I.G.H.
Randeree, G. Ramjee, Y.K. Seedat, H.M. Coovadia, and M. Adhikari,
Departments of Medicine and Pediatrics, University of Natal and King
Edward Viii Hospital, Durban, Natal, Republic of South Africa.
Proteinuria results from loss of size, shape or charge selectivity of the
glomerular polyanion (GP). Erythrocytes possess similar anionic
charges to GP. Thus, it is possible to indirectly infer glomerular
pathology by assessing erythrocyte binding to cationic dyes like alcian
blue (AB). A reduction of AB-binding of erythrocytes has been docu-
mented in children with nephrotic syndrome (NS) but not conclusively
studied in adults. This study was undertaken to assess AB-binding of
erythrocytes in adults with NS and to correlate the degree of AB-
binding with serum albumin, serum creatinine and proteinuria. A group
of 15 adults with NS (due to pre-eclamptic toxemia (PET) or 1°/2° forms
of glomerulonephntis and 15 age, sex and race matched controls were
prospectively studied. A sample of venous blood was obtained; this was
evaluated for AB-binding by a single blinded investigator. There was a
significant reduction in the AB-binding of nephrotics compared to
controls (P 0.039; Wilcoxon 2 sample test.)
Groups
Mean AB-binding
to erythrocytes
P
value
Nephrotics 21.6 12.6 ngIlO6 cells 0.039
Controls 34.2 20.2 ngIlO6 cells
There was no correlation between proteinuria, serum albumin, serum
creatinine and the degree of AB-binding. This study confirms decreased
AB-binding of erythrocytes in adult nephrotics. It also permits further
research into pathogenetic mechanisms of proteinuric states where
renal biopsy is not routinely performed, such as PET and diabetic
nephropathy.
Renal amyloidosis: A renal biopsy study. M.D. Pascoe, CR. Swane-
poel, and R. van Zyl-Smit, Renal Unit, Groote Schuur Hospital and
Department of Medicine, University of Cape Town, Cape Town, South
Africa. The aim of this study was to determine the frequency of
amyloidosis in patients undergoing renal biopsy at a single center, since
the incidence of renal amyloidosis differs widely in various renal biopsy
studies, and to define the clinical features and associations with
amyloidosis in the population served by this hospital. Patients with a
diagnosis of amyloidosis on a renal biopsy were identified from a
computerized database, and the clinical records reviewed for the
clinical and laboratory features of the disease at the time of presenta-
tion. The diagnosis of renal amyloidosis was made on the finding of the
characteristic apple green bi-refringence on polarized light examination
of congo red stained sections. This diagnosis was confirmed by electron
microscopic study in the majority of cases. Between January 1977 and
December 1990, a total of 1640 renal biopsies was performed for the
evaluation of glomerular disease. In 24 cases the diagnosis was of
amyloidosis (1.46%). Of these patients 13 were male, 11 female, and the
mean age was 42 years (range 18 to 68 years). Amyloidosis was
associated with destructive pulmonary tuberculosis in 10 patients
(42%), rheumatoid arthritis in two (8.33%), and bronchiectasis without
evidence of tuberculosis and myeloma in one (4.17%) each. In nine
(37.5%) patients the diagnosis of primary amyloidosis was made in the
absence of any disease known to be associated with amyloidosis. At
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presentation plasma creatinine was 335 93 mols/liter, including nine
(37.5%) patients with plasma creatinine >150 tmols/liter, proteinuria 6
1 g/day, including 16 patients (66%) with proteinuria >3.5 g/day and
three (12.5%) <1 glday, plasma albumin 22 2 g/liter, including 16
(66%) with plasma albumin <25 gtliter, (Means SEM). Hematuria was
present in 15 (62.5%) patients, and in 12(50%) cases, casts were present
on the initial urine examination. In four patients diastolic hypertension
(>90 mm Hg) was noted, three of whom had abnormal plasma creati-
nine at the time of diagnosis. Renal biopsy was not complicated by
hemorrhage in any of these patients. The incidence of amyloidosis is
lower at our hospital than that reported from Durban (3%) and that
reported from India (8.4%) in biopsied patients. There is a wide clinical
spectrum of renal amyloidosis at presentation. Although renal failure is
commonly present at diagnosis, and hypertension and hematuria are
also found, renal biopsy is considered safe for these patients.
Hereditary interstitial nephritis without basement membrane changes.
N.T. Levy, A.M, Meyers, L.P. Margolius, S. Verhaart, and W.A.
Wadee, Departments of Nephrology, Anatomical Pathology and Im-
munology, Johannesburg Hospital, University of the Witwatersrand
and SAIMR, Johannesburg, South Africa. Hereditary interstitial ne-
phritis (HIN) is a heterogenous group of disorders comprised of
medullary cystic disease, several varieties of Alport's Syndrome, and
also one familial disorder with a distinct clinical syndrome and without
basement membrane changes, described in Australia in 1981. Our
family consisted of ten siblings, five of which presented with renal
dysfunction of varying degrees (three females and two males). Of the
five unaffected siblings, one brother was killed in a motor vehicle
accident and the whereabouts of another brother is unknown. One
sibling (female) required renal transplantation, subsequent to end-stage
renal disease (related living donor transplant from one of the unaffected
female siblings). With regard to the parents, the father died of renal
failure years ago, while the mother is presently alive and well. The
investigations performed included full blood count and platelets, renal
function tests, protein electrophoresis, collagen screen, parathyroid
hormone, l,25(OH)2D3 and arterial blood gas analyses. Twenty-four
hour urine specimens were analyzed for biochemistry, including B2
microglobulin and amino acids. Radiological studies of the affected
patients included ultrasonography and CT scans. Renal biopsies were
performed in two of the affected patients, where cores of renal tissue
were examined by light microscopy, immunofluorescence and transmis-
sion electron microscopy. Visual and auditory examinations have been
performed on the whole family while HLA typing was awaited. Clini-
cally, the affected siblings presented with long standing hypertension,
minimal proteinuria, hematuria and no other features of Alport's
Syndrome. The biochemical tests have excluded all known causes of
secondary diffuse interstitial nephritis and there were no clinical,
hematological or biochemical features of Alport's Syndrome. Sonogra-
phy and CT scanning excluded medullary cystic disease. Renal biopsy
showed the typical features of a chronic interstitial nephntis without
basement membrane changes, which were identical to those initially
described by Richmond et al. The renal interstitium showed moderate
to severe fibrosis with tubular atrophy and chronic inflammation
presenting with a predominantly lymphocytic infiltrate. Transmission
electron microscopy confirmed the absence of any basement membrane
changes. In conclusion, we have presented a second family where the
known causes of secondary diffuse interstitial nephritis, Alport's Syn-
drome and medullary cystic disease have been excluded, and the
presence of HIN without basement membrane changes has been
confirmed. The disease appears to be inherited in an autosomal domi-
nant pattern, but further characterization is required.
The effect of citrate (Ci)-contalning calcium preparations on intestinal
aluminium (Al) absorption. A. W. Nestel, A.M. Meyers, J, Paiker, and
H.B. Rollin, Division of Nephrology, University of Witwatersrand and
Johannesburg Hospital, SAIMR and NCOH, Johannesburg, South
Africa. Al toxicity continues to be a major problem in patients with
chronic renal failure and can cause crippling bone disease and poten-
tially fatal encephalopathy. Ci has been shown. to enhance GIT Al
absorption 100-fold. The aim of this study was to determine whether Ci
content of the frequently used 'Ca-Sandoz" tablets increases intestinal
absorption of Al. Serum concentrations and 24 hour urinary excretion
of Al were measured via graphite furnace atomic absorption spectro-
photometry in 2 groups of subjects: Group 1, 10 normal controls; Group
2, eight undialyzed stable chronic uremics. Al measurements were
performed in four experimental circumstances, namely ingestion of: (1)
CaCO3 (1000 mg Ca/day), (2) Ca-Sandoz + Al (OH)3. The results from
Group 1 (controls) are shown in the Table.
CaCO3
(Basal) Ca-Sandoz
CaCO3 +
A1(OH)3
Ca-Sandoz +
Al(OH)3
Serum Al 10.7 (5) 10.5 (6) 14.1 (3)' 26.3 (13)ab
24 hr urine 10.0(8) l2.8(18.l)a 70.4(3.7)' 193 (73)'
P < 0.007; Basal vs. other
' P < 0.027
Group 2 results will be shown. Thus far in the study we conclude that
Ca-Sandoz greatly enhances Al absorption, which we predict will
elevate serum levels in uremics into the toxic range. The formulation of
this and similar products must be modified and Ci removed.
The pattern of CAPD Infections in Durban. S. Naicker, I.P. Naiker, L.
Botden, A.A. Haffejee, and Y.K. Seedat, Renal Unit, Addington
Hospital and University of Natal, Durban, South Africa. Since the
inception of CAPD in Durban in 1978, peritonitis remains the major
limitation in the success of CAPD. We undertook a two year study
(from January 1990 to December 1991) of CAPD patients at the Renal
Unit at Addington Hospital, to study the seasonal variation (if any) in
the incidence and the type of infections and the associated morbidity
and compared the data to that of earlier years.
Gram + Gram — Fungal Culture — Total
Peritonitis
1991 46 (32.2%) 58 (40.6%) 6 (4.2%) 33 (23%) 143
1990 46 (41%) 28 (25%) 4 (3.6%) 34 (30.4%) 112
1987 47 (61%) 23 (30%) 7 (9%) 87
1980— 50% 15% 3 24.6% 239
1984
1981— 42.5% 31.5% 0.7% 26% 134
1982
Catheter tract and exit site infection
1991 23 (52.3%) 20 (45.5%) 1 44
1990 38 (77.6%) 11(22.4%) 49
Catheter removal
1991 8 17 6 1 32
1990 11 9 3 2 26
Infection did not respond to treatment, and the Tenckhoff catheter was
removed in 11.1% of S. epidermidis, 31.7% of S. aureus, 44.4% of
Pseudomonas, 60% of Klebsiella, 57.1% of Serratia, 90% of Candida,
and 4.4% of culture negative infections. The frequency of peritonitis
appeared to increase in spring and summer. Gram negative infections
occurred in increasing frequency in 1991 and resulted in an increased
incidence of catheter loss.
The Groote Schuur experience with the Y flush before fill system. B.L.
Rayner, M. May, and G. Fortuin, Renal Unit, Groote Schuur Hospital,
Cape Town, South Africa. Recent reports from Europe and North
America suggest that the Y system (either disconnect or flush before fill
with disinfection) is associated with a dramatic reduction in peritonitis
rates. Until recently, no commercially available Y system was in use in
South Africa. In January 1991 SABAX introduced the flush before fill Y
system with amuchina disinfection (system 3), and this report evaluates
the Groote Schuur experience. From February 1991 all new patients
entering the CAPD program at Groote Schuur Hospital were com-
menced on system 3, and the clinical outcome and complications were
prospectively documented and compared to historic data over the
preceding four years using the straight bag system. To date 29 patients
(16 females and 13 males with a mean age of 43 years) have entered into
the study. The causes of renal failure were chronic glomerulonephritis
(12), diabetes (7), systemic lupus erythematosus (4), and miscellaneous(6). Patients have been followed for a mean of 160 days (range 16 to
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422). Two patients have been transplanted, one has died, and one was
transferred to hemodialysis because problems of under dialysis. Only
eight episodes of peritonitis (7 S. aureus) have been recorded with a
mean rate of 0.05 episodes/patient month compared to a historic rate of
0.22. There were 16 exit site infections (10 S. aureus and 5 S.
epidermidis) with a mean rate of 0.1 episodes/patient months, which is
the same as the historic rate. System 3 was well tolerated by the
patients with only two cases of amuchina instillation into the peritoneal
cavity, which caused acute pain, but no long-term sequelae. In conclu-
sion, the introduction of system 3 caused a profound decline in
peritonitis rates, but not exit site infection compared with historic data.
This is in line with data reported elsewhere and has important implica-
tions for patient well-being and technique survival in South Africa.
Protein catabolic rate in continuous ambulatory peritoneal dialysis
(CAPD) patients. J. Jacobs, C. Edeistein, R. Moosa, J. van Zyl, and D.
Labadarios, Departments of Internal Medicine and Human Nutrition,
University of Stellenbosch; and Renal Unit, Tygerberg Hospital, South
Africa. Chronic renal failure patients on continuous ambulatory perito-
neal dialysis (CAPD) can develop protein energy malnutrition and
muscle wasting due to inadequate dietary protein intake and/or excess
protein losses in the dialysate fluid during episodes of acute peritonitis.
Protein catabolic rate (PCR) measurements can be used to assess
protein metabolism. The aims of study were: (1) To determine the PCR
in CAPD patients by using a urea kinetic modelling formula; and (2) To
validate this formula for PCR by comparing the dietary protein intake
(DPI) with the PCR measurement which should be comparable in a
patient in a stable metabolic state. Eight CAPD patients in a stable
metabolic state were studied. The PCR was determined by measuring
urea nitrogen appearance (UNA) in peritoneal fluid and residual urine.
DPI was recorded by foodtray analysis and a Foodfinder computer
program was utilized to calculate the protein content of the food. The
mean PCR of the group was 62.1 g/day compared to a mean dietary
protein intake of 61.7 g/day. In all the studies done the DPI compared
closely with the kinetically determined PCR. The average protein intake
of the group was 1.06 g/kg/day, compared to the recommended DPI of
1.2—1.5 g/kg/day. The conclusions were: (I) PCR measurements can
predict the DPI in stable CAPD patients. The PCR may be used to
determine the dietary protein needs in CAPD patients. (2) Determina-
tion of PCR using a urea kinetic modeling formula is a useful test in
CAPD patients that uses readily available data.
Platelet function, fibrinolytic and coagulation studies in patients on
chronic peritoneal dialysis. V. van Wyk, H.F. Kotze, B.P. Botha, J.P.
Roodt, and P.N. Badenhorst, Department of Haematology and Inter-
nal Medicine, U.O.F.S., Bloemfontein, South Africa. Patients with
chronic renal failure have an abnormal bleeding tendency which may be
ascribed to the high levels of urea in the plasma. The aim of this study
was to investigate the components of hemostasis in 7 patients (5 men)
on continuous ambulatory peritoneal dialysis (CAPD). All patients had
normal platelet counts (288 55 x 109/liter) with high plasma urea (20.1
2.1 mmol/liter) and creatinine (988 261 imol/liter) levels. The tests
to determine the hemostatic status included: platelet function tests,
fibrinolytic markers and coagulation status. Results are given as a mean
I SD with the normal reference values or ranges in brackets. All
coagulation parameters were normal except for the fibrinogen levels
which were slightly elevated: APTT, 32 4 s (30—40 s); PT, 13 1 s
(12—16 s); TT, 32 5 s (28—32 s); antithrombin III, 112 29%
(80—120%); and fibrinogen, 5.5 2.0 g/liter (2.0—4.0 glliter). Fibrinolysis
was also normal: plasminogen, 113.3 16.8% (80—120%); alpha-2-
antiplasmin, 115.6 23.8% (80 120%); d-dimer, <0.5 g/ml (<0.5
g/ml); plasminogen activator inhibitor, 5.5 3.6 Jml (0—8 tJm1); and
tissue plasminogen activator, 9.6 4.4 ilml (1—12 s/m1). Platelet
function tests revealed interesting differences. Bleeding time was sig-
nificantly prolonged at 8.2 4.1 minutes (4.1 1.1 mm). The MPLS
was significantly shorter at 170 40 hours (224 23 hr; P < 0.001). The
in vitro aggregation response of platelets to the lower ADP concentra-
tions were significantly higher than normal, but it was lower when a
high collagen concentration (4.0 g/ml) was used as agonist: 74.6
4.2% (87.9 2.2%). Patients on CAPD had a tendency of increased
spontaneous platelet aggregation, 17 6% (7 3%; P < 0.001), and
also significantly more circulating platelet aggregates, 0.74 0.06 (0.96
0.03). These results indicate that fibrinolysis and coagulation do not
contribute markedly to the bleeding tendency of uremic patients; the
bleeding tendency should be ascribed to platelet adhesion impairment.
Atherosclerosis is one of the main causes of death in patients with
chronic renal failure, and this may be reflected by the results on platelet
function, that is, short MPLS, more circulating platelet aggregates, and
increased spontaneous aggregation and sensitivity of platelets to ADP.
Systemic lupus erythematosus in patients on peritoneal dialysis at
Groote Schuur Hospital. D. Miller, B. Rayner and C. Swanepoel, Renal
Unit, Groote Schuur Hospital and Department of Medicine, University
of Cape Town, Cape Town, South Africa. Dialysis and transplantation
has become acceptable practice for patients with systemic lupus cry-
thematosus (SLE) who reach end-stage renal failure. Since 1974,
numerous reports have appeared in the literature showing a significant
reduction in disease activity in SLE patients once they are on hemodi-
alysis. A few studies that have looked at SLE patients on peritoneal
dialysis (PD) have been unable to confirm a similar reduction in activity
in these patients. A retrospective review was undertaken of SLE
patients at Groote Schuur Hospital who were started on PD between
1980 and 1992. All the patients fulfilled the American Rheumatism
Association revised criteria for SLE, and all except one had at least one
renal biopsy which confirmed an active lupus nephritis. Lupus flares
were defined as an increase in disease activity severe enough to warrant
commencing or increasing immunosuppressive therapy. These flares
were usually clinical, but serological activity invariably confirmed
significant disease activity. The lupus flare per year rate for each patient
was calculated and a comparison made between the period before and
after dialysis was commenced. Results. There were 13 Black patients,
12 females and one male, and two Whites, one male and one female
(total 15). The mean age at diagnosis was 25.8 years (range 10.1—36.0)
and at first dialysis was 31.1 years (range 14.1—53.8). The duration of
SLE before dialysis was 5.3 years (range 0.1—40.6) and the mean time
on dialysis was 1.5 years (range 0.1—5.8).
Before
Mean
dialysis
Total
After
Mean
dialysis
Total
Number of flares 3.9 55 0.9 13
Time years 5.3 79.43 1.5 22.8
Flare rate per year 0.69 0.57
At the time of analysis, 4 patients were still on CAPD, 1 had recovered
function and was off dialysis, 6 had had renal transplants and 4 had died.
Peritoneal and exit site infection rates in these patients was compared
with the average rate for the unit during the same period. The patients
had an exit site infection rate of 0.58 per patient year, with a control of
1.0, and peritonitis rate of 2.26 per patient year with a control of 2.64.
Conclusion. Peritoneal dialysis is a safe and effective way of dialyzing
SLE patients and the complication rate is no higher than other patients.
There was no statistically significant difference in the disease activity of
SLE patients before and after commencing CAPD.
In vitro erythropoietin (EPO) production by HEP G2 cells is inhibited
by monocyte supernatant from patients with renal failure—Preliminary
data. M.J.D. Cassidy, 0. Ebrahim, C. de Jager, S. Robson, Renal and
Liver Units, Department of Medicine and Pharmacology, University of
Cape Town and Groote Schuur Hospital, Cape Town, South Africa.
Anemia is invariably associated with both acute and chronic renal
failure. Decreased production of EPO by the kidney is the most widely
accepted mechanism for the inability of the red cell precursors to
proliferate in response to anemia. Inhibitors to EPO may in addition
accumulate in uremia and interact with EPO. In this study we show that
supernatant from monocytes cultured from patients with chronic renal
failure inhibit EPO release by HEP G2 cells in vitro. Ten patients with
chronic renal failure consisting of 5 males and 5 females mean age 42
years (range 25—60) were studied. Five were approaching end-stage
renal failure and 5 were maintained on hemodialysis. Blood was taken
from Hb and EPO levels. Monocytes were extracted from 45 ml blood
for culture using standard techniques. Monocyte supernatant (MS) was
harvested at 48 hours before and after stimulation with LPS. HEP G2
cells were cultured and incubated with MS from patients and controls(N = 8). After 24 hours this supernatant was analyzed from EPO,
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expressed as a function of total cell protein (dmg). EPO production
was inhibited by pre-LPS stimulated MS compared to controls (49.8
18.7 vs. 123.1 18.4; P =<0.0001). This was even more profound after
LPS stimulation (11.9 1.3 vs. 113.2 41.7, P =<O.000i). TNF levels
(pglml) were measured in MS and predictably rose after LPS stimula-
tion. Though we could not demonstrate a significant correlation be-
tween MS TNF levels and EPO production, addition of polyclonal
anti-TNF antibody reversed inhibition in three patients studied. In
conclusion, we demonstrated that monocytes cultured from patients
with chronic renal failure secrete cytokines that inhibit EPO production
by HEP G2 cells. Though TNF may be implicated, the lack of
correlation between TNF concentration in the supernatant and inhibi-
tion of EPO production suggest that other factors may be responsible.
Further studies are ongoing to determine the role of TNF, if any, in this
phenomenon.
Effects of exercise training and recombinant human erythropoietin
(EPO) in patients receiving chronic haemodialysis, M. V. Sam, C. Swane-
poel, T.D. Noakes, Liberty Life Chair of Exercise and Sport Science
and the MRC/UCT Bioenergetics of Exercise Research Unit, Depart-
ment of Physiology, University of Cape Town Medical School and the
Renal Unit, Department of Medicine, Groote Schuur Hospital, Obser-
vatory, South Africa. To investigate the effects of recombinant human
erythropoietin (EPO; REPOTIN, Continental Ethicals (PTY) Ltd.,
Johannesburg, South Africa) on the exercise tolerance of patients with
end-stage renal disease receiving chronic haemodialysis, five patients
with stable chronic end-stage renal failure receiving maintenance he-
modialysis were studied during a 6-month exercise training program
prior to EPO treatment, and for a further 3 months when they continued
to train while receiving EPO. Patients exercised on a stationary bicycle
ergometer while receiving hemodiaiysis. Peak rates of oxygen con-
sumption (ml O2Ikg/min) and maximum workload achieved (W) during
maximal exercise increased significantly after the 6-month training
program (15.4 2.5 vs. 19.8 2.3 [mean SD] ml 02/kg/min; P <0.01;
57.0 17.5 vs. 78.0 14.7 W; P < 0.01); a further 27% increase (P <
0.01) was observed after 3 months of EPO treatment. There was a
significant correlation (r = 0.75 to r = 0.82; P < 0.01 to P < 0.001)
between peak muscle strength and peak workload achieved during
maximum exercise. At any given workload, ventilation, heart rate,
serum lactate concentration were all reduced, as were resting and
maximum systolic blood pressures. No changes occurred in hematocrit
or hemoglobin with training prior to EPO administration, and no
adverse events occurred during or after exercise. EPO treatment
increased mean hemoglobin (5.2 0.2 vs. 7.4 1.8 gIdl; P < 0.05), and
hematocrit levels (15.8 vs. 22.6%; P < 0.05) by 43%. We conclude that:
(a) exercise training during hemodialysis treatments is safe; (b) muscle
strength is a predictor of exercise capacity in renal dialysis patients
receiving chronic hemodiaiysis; (c) exercise training increases physical
work capacity and improves blood pressure control; (d) EPO partially
corrects anemia and increases physical working capacity; and (e) the
mechanism for increased skeletal muscle function in hemodialysis
patients is not currently known.
Role of urinary copper and phosphorus in kidney stone formation. A.
Rodgers, L. Barbour, M. Pougnet, C. Lombard, and R. Ryall, Depart-
ment of Chemistry, University of Cape Town, Cape Town, South
Africa. Past attempts to distinguish between stone formers (SF) and
normals (N) on the basis of urinary component concentrations have
failed to demonstrate consistent differences between the groups. One
avenue not fully explored is that of urinary elements. Since the
presence of any element in a kidney stone suggests that it may have
fuffilled some determinant role in the stone's pathogenesis, the present
study was undertaken to establish whether differences exist between
stone formers and controls with respect to their excretion of such
elements. Nineteen male calcium oxalate stone formers and 20 healthy
male controls participated in the study. Early morning urines were
collected for convenience and because they were more likely to reveal
differences than 24 hr collections as a result of their more concentrated
nature. Subjects collected urines on 3 consecutive mornings (Mon,
Tues, Wed) to compensate for random daily fluctuations in urine
composition. The concentrations of several elements were determined
by inductively coupled plasma atomic emission spectroscopy and
graphite furnace atomic absorption spectroscopy. Only those elements
which have been detected in stones or urine and for which we have an
analytical capability were analyzed. Data were treated using multivari-
ate statistical methods. The results showed that the urinary concentra-
tions of several elements varied on a daily basis. However, only Cu and
P values were significantly different on all three days: Cu concentra-
tions were significantly higher in the stone formers while P values were
significantly lower. It is interesting to speculate how these two elements
might be determinant factors in urolithiasis. As far as Cu is concerned,
it is noted that it is a common constituent of kidney stones, occurring in
approximately 80% of those analyzed for its presence. Moreover, its
concentration in kidney stones is approximately 1000 times greater than
in urine, thereby suggesting that it fulfills an active promotory role in
stone formation. Indeed in vitro studies have shown that Cu promotes
calcium oxalate dihydrate formation by incorporation into the crystal
lattice. Another possibility is that Cu could become incorporated into
the gross architecture of a stone by virtue of it being a structural
component of protein molecules which are released into the urine in
response to cellular injury caused by the growing stone and which
themselves then bind to the crystal surfaces. Irrespective of the
explanation, it is apparent that a raised concentration of Cu in the urine
should increase the likelihood of its presence in urinary stones. Phos-
phorus is a major constituent of renal calculi where its concentration far
exceeds that of urine. Although it is reasonable to assume that an
abnormally high renal excretion of phosphorus would increase the
likelihood of phosphate precipitation, our results show that stone
formers have significantly lower values. Similar results have been
reported by other workers. It has been hypothesized that low urinary
phosphate excretion is indicative of high urinary Ca excretion. Con-
versely, it has been shown that urinary Ca decreases during P supple-
mentation. Indeed, phosphate therapy has been successfully used in the
treatment of Ca stones. We suggest that the lower urinary concentra-
tions of P in stone formers might also be indicative of lower concen-
trations of pyrophosphate, a recognized inhibitor of calcium oxalate
crystallization.
Urinary excretion of glycosaminoglycans in normal Black and White
subjects and in recurrent renal stone formers. A.M. Meyers, N, Whalley,
M. Martins, and L.A. Margolius, Department of Nephrology, Johan-
nesburg Hospital and University of Witwatersrand, South Africa. Renal
calculi form via the processes of crystal nucleation, aggregation and
growth. Urinary supersaturation and inhibitor deficiencies constitute
important risk factors. We and others have shown a pivotal role played
by reduction in the urinary concentration of small molecular weight
inhibitors, such as, citrate, pyrophosphate and Mg, in the pathogenesis
of recurrent renal calculi. In patients with single oxalate calculi,
macromolecular weight inhibitors such as glycosaminoglycans (GAG)
and crystal matrix protein have been shown to be markedly reduced in
concentration. However, much controversy exists about urinary GAG
levels in patients with recurrent oxalate calculi. Low, normal or even
raised levels have been reported. Additionally, nothing is known about
GAG levels in Black normals and recurrent stone formers, and in
particular, whether, if the normal population has high GAG levels, this
could be protective towards the low incidence of renal calculi in the
Black population. For this reason, we have studied urinary GAG
excretion in Black and Caucasian normals (Groups Cl & C2 and Black
and Caucasian recurrent stone formers (P1 & P2). Aliquots of 24 hour
urines and early morning 'spot" specimens collected without preser-
vative and on the patients usual diet were stored -20°C. Urine was
purified and GAG precipitated with CPC solution. Total GA was
measured via a modified method of glucuronic acid determination.
Further aliquots were stored for component GAG measurement via
HPLC, that is, chondroitin and heparan sulphate and hyaluronic acid.
P
Collection Group N GAG value
"Spot" mg/g creat Cl
C2
16
16
4.24 (1.04)
2.92 (0.95)
<0.05
24 hr mg/g creat
Micro-mol 24 hr
P1
P2
C2
P2
5
29
17
29
9.67 (11.4)
5.69 (2.4)
21.65 (7.3)
43.05 (15.5)
NS
<0.05
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Thus, these preliminary results suggest that GAG levels are signifi-
cantly higher in Black normals, but that both Black and Caucasian stone
formers have, in fact, higher concentrations of urinary GAG than the
normal population. The reasons for this are not known. However, more
numbers are required, particularly in Black patients, before definite
conclusions can be drawn. In addition, "spot" specimens must be
validated with 24 hour urines, and HPLC GAG must be analyzed as one
or more of the GAG components which could be the critical factor
conferring protection.
A clinical trial comparing the treatment of hypercholesterolemia with
simvastatin and diet versus diet alone in patients with idiopathic mem-
branous nephropathy: A preliminary report. B.L. Rayner, M. Byrne, R.
van Zyl-Smit, Groote Schuur Hospital and University of Cape Town,
Cape Town, South Africa. The nephrotic syndrome is characterized by
hypercholesterolemia. Few data are available on the treatment of this
complication and its effect on renal function. The aim of this study was
to determine whether simvastatin, a new HMG co-reductase inhibitor,
could safely lower serum cholesterol levels and retard the progression
of renal disease in patients with idiopathic membranous nephropathy
(IMN). Patients with biopsy-proven IMN, serum cholesterol >6.1
mmol/liter and serum creatinine <200 mol/liter, were alternately
assigned to treatment with simvastatin and diet, or diet alone. All
patients received standard supportive care. Simvastatin (10 mg) was
begun in the treatment group after an initial run in period of 3 months
and increased by 10 mg to a maximum dose of 40 mg at 3 monthly
intervals until the serum cholesterol was <5.1 mmolfliter. All patients
were monitored at 3 monthly intervals for the following parameters:
urea, creatinine, 24 hour proteinuria, creatinine clearance, total choles-
terol, triglycerides, LDL, HDL, apoA and apoB. A labeled
EDTA clearance was done at 6 monthly intervals. To date 7 patients
have been entered into the drug arm and 6 into the diet alone. Median
follow up is 9 months. The mean results of the initial 12 months are
shown in the Table below. The diet alone group is shown first for each
parameter.
Time
months 0 3 6 9 12
Albumin 27 23 27 24 28
gluIer 28 30 27.6 31 40
Upr/Ucr 0.59 0.59 0.55 0.59 0.82
ratio 0.52 0.49 0.39 0.39 0.14
Cholesterol 9.7 10.3 10.1 9.0 12
mmol/liter 9.5 8.5 7.7 6.6 5.1
HDL 1.1 1.1 1.0 0.9 1.0
mmol/liter 1.2 1.1 1.2 1.11 1.23
LDL 8.16 8.36 9.2 7.7 9.9
mmol/liter 6.7 6.0 4.9 3.6 3.0
Creatinine 98 101 114 121 111
umol/liter 105 106 106 114 167Cr EDTA 77 60 77
mi/mm/i .73 85 69 61
m2
Simvastatin was well tolerated by all patients and the average dose
required to normalize cholesterol was between 20 and 30 mg. In
conclusion, this preliminary report suggests that simvastatin can safely
lower cholesterol in nephrotic patients with IMN. No conclusion can be
reached at this stage on its effect on renal function.
Changes in serum cholesterol following renal transplantation. R. van
Zyl-Smit, Renal Unit Groote Schuur Hospital and Department of
Medicine, University of Cape Town, Cape Town, South Africa. Most
early studies of post-transplant hyperlipidemia have noted increased
levels of triglycerides in up to 70% of patients. Both corticosteroids and
cyclosporine seem to cause hypercholesterolemia; This effect is vari-
able and the relative importance of these two agents has not been
conclusively established, largely because they are almost always used
in combination. In the group of 124 post-renal transplant patients
studied, cyclosponne was used in combination with azathiopnne and
prednisolone for the first 6 months only; it was then stopped. At the
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time of stopping the prednisone dose ranged between 20 and 24 mg/day.
During the changeover, azathioprine was either started or if the patient
was already receiving this agent the dose was doubled from 50 to 100
mg/day. The prednisone dose was transiently increased to between 28
and 32 mg/day, but then rapidly tailed off. By the end of the year the
mean prednisone dose was 14 mg/day. By three months following
transplantation, the cholesterol had risen from a mean of 5.08 mmol/
liter (pre-transplant) to 6.01 mmol/liter (P < 0.0001). By 6 months the
mean cholesterol had risen even further to 6.30 mmol/liter. By the end
of the first year, cyclosporine had been stopped for a period of 6 months
and the steroid dose reduced to a mean of 14 mg/day, yet the mean
cholesterol level was now 6.42 mmollliter. Even at 4 years the mean
level was still 6.30 mmol/liter despite a low-maintenance steroid dose of
less than 10 mg/day. The pre-transplant cholesterol was not related to
the magnitude of the subsequent rise, but those with a pre-transplant
cholesterol level of less than 5 mmol/liter rarely rose into a category
suggesting high risk (>7 mmol/Iiter). The greatest percentage rise in
cholesterol was seen in White males (49%), with the least in colored
females (15%) and in Black females (25%). Colored females had the
highest mean pre-transplant levels (5.67 1.48 SD) and Black females
the lowest mean (4.18 0.49 SD). In the 124 patients studied, 20
developed levels above 6.5 mmol/liter, 17 levels above 7.0 mmol/liter, 9
levels above 7.5 mmol/liter, 19 levels above 8 mmol/liter and 7 had
levels above 9 mmol/liter. Conclusions. Despite stopping cyclosporine 6
months following transplantation, hypercholesterolemia remained a
major problem in at least 50% of the patients. It was clearly not related
to the steroid dose. The groups at greatest risk of having excessively
high levels (>7 mmol/liter were White males, White females and
colored males. Maximum levels may only be reached 2—4 years after
transplantation, suggesting that careful and continuous monitoring
would be required if these patients were to be selected for treatment.
The effect of hormonal changes on bleeding times of renal failure
patients. B.P. Botha, MW. Fockema, H.G. Vilfoen, Department of
Internal Medicine, Division of Nephrology, UOFS, Bloemfontein,
South Africa. A bleeding diathesis complicates the management of
some patients with renal failure. Prolonged bleeding times can be
reduced when estrogen is administered to these patients. The aim of the
study was to investigate the role of gender and hormonal profiles on
bleeding times of patients on maintenance hemodialysis. A prospective
study including all patients on hemodialysis was started. Bleeding
times, hematological and biochemical profiles were done. Plasma levels
of estrogen, FSH, LH, prolactin, progesterone PTH and testosterone
hormone were measured. All female patients had amenorrhea for at
least 6 months and all patients were on maintenance hemodialysis for at
least 6 months. Thirty-nine patients were included in the study.
Nineteen (49%) had prolonged bleeding times and 13 (62%) of these
were males. Twenty patients had normal bleeding times, 12 of these
(67%), were female. The estrogen concentrations of male (634 pmol)
and female patients (616 pmol) with normal bleeding times were
significantly higher than those of patients with prolonged bleeding times
(182 and 185 pmol). Testosterone (22 nmol/liter) and progesterone (3.8)
concentrations were significantly higher in males with normal bleeding
times, though were still in the normal range. LH (48.7 sJm1) and FSH
(92 MImI) were significantly higher in females with normal bleeding
times. No significant differences in PTH and prolactin concentrations
and platelet counts were found. Conclusion. Prolonged bleeding times
are more common in male patients in our dialysis population. Estrogen
levels are higher in both male and female patients with normal bleeding
times. Elevated plasma estrogen concentrations appear to play a role in
the prevention of the bleeding diathesis in renal failure patients.
The arachidonic acid metabolism in platelets of uremic patients with
prolonged bleeding times. B.P. Botha, F.C. Cloete, and P.N. Baden-
horst, Department of Internal Medicine, Division of Nephrology,
Department of Haematology, UOFS, Bloemfontein, South Africa.
Some uremic patients develop a bleeding diathesis. Decreased platelet
thromboxane A2 (TxA2) production is one of the major causes of the
thrombopathy. A defect in the platelet arachidonic acid (Aa) metabo-
lism appears to be involved in the abnormal platelet function. Platelet
cyclo-oxygenase activity is normal in platelets of uremic patients. The
defect in TxA2 production must then be proximal to cyclo-oxygenase in
the metabolism of Aa. The aim of the study was to determine the
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concentrations of Aa in plasma and platelets and the activity of
arachidonyl CoA synthetase in platelets of uremic patients with pro-
longed bleeding times. Platelets and plasma of 10 uremic patients with
prolonged bleeding times (12 min+) on maintenance hemodialysis, and
10 normal persons were analyzed. Fatty acids were determined by GLC
and the activity of arachidonyl CoA synthetase determined by measur-
ing the incorporation of 3H labeled Aa into the platelet phospholipids.
Phospholipids were separated by HPLC and 3H AA measured by a
radio activity flow meter. Normal platelets were incubated in uremic
plasma and uremic platelets incubated in normal plasma. Uremic
plasma was dialyzed in the laboratory against membranes with perme-
ability for molecules with a molecular mass of less than 1000 and 3500
daltons and platelets were then incubated in the dialyzed plasma. Aa
incorporation in platelet phospholipids were then determined. Uremic
plasma contains significantly more unesterified Aa (P < 0.001) and
uremic platelets significantly less AA (P < 0.001) than the control
group. Arachidonyl CoA synthetase activity is reduced in uremic
platelets (P < 0.002). This abnormality in enzyme activity was reversed
by the incubation of uremic platelets in normal plasma. The defect in
enzyme activity was induced in normal platelets by incubation in
uremic plasma. Incubation of platelets in dialyzed plasma had no effect
on enzyme activity. Conclusion. A factor in uremic plasma with a
molecular mass of less than 1000 daltons inhibits the activity of
arachidonyl CoA synthetase. The decreased activity of arachidonyl
CoA synthetase in uremic platelets leads to the low concentrations of
Aa in uremic platelets in spite of an increased Aa concentration in
uremic plasma. The decreased production of TxA2 in uremic platelets is
caused by the low concentration of Aa in the platelet membrane.
A comparison of intravenous cyclophosphamide with oral cyclophos-
phamide for the treatment of lupus nephritis. An interim report. M.R.
Moosa, A. Halland, C. Edeistein, W. Bates, Departments of Internal
Medicine and Anatomical Pathology, University of Stellenbosch, Renal
and Rheumatology Units, Tygerberg Hospital, Cape Town, South
Africa. Lupus nephritis is a serious complication of systemic lupus
erythematosus (SLE), with a significant morbidity and is a common
cause of mortality. Steroid treatment has resulted in an improvement in
the outcome, but does not work for all patients, and is accompanied by
significant side-effects at higher doses. We evaluated the clinical and
pathological effect of using monthly intravenous cyclophosphamide
(i.v.CY) compared to daily oral cyclophosphamide (p.o.CY), together
with low dose steroids in 11 patients. This is a report of the first six
months of follow-up. Patients with newly diagnosed, biopsy proven,
proliferative (WHO classes III and IV) or severe membranous (>1 g
proteinuria) lupus nephritis were randomized to receive either i.v.CY or
p.o.CY. The doses were adjusted to maintain a neutrophil count 3 to
4000/mi. The patients were monitored for clinical and biochemical
responses to treatment, as well as adverse effects. The renal biopsy was
repeated at six months. Six patients received i.v.CY and five p.o.CY
after pulse Solumedrol therapy. Marked clinical improvements were
noted in both groups of patients. Biochemical and pathological data at
initiation of treatment and six month follow-up of the two groups is
shown in the accompanying Table:
I.V.C
Entry
Y (N = 6)
Follow-up
P.O.C
Entry
Y (N = 5)
Follow-up
Serum creatinine 140 86 105 82
Protein excretion/24 hrs 2.8 0.79 2.3 0.9
C3 61 97 71 101
ESR 104 73 74 38
Activity index 5.6 3.0 6.8 3.2
Chronicity index 2.0 3.4 2.2 3.0
Results are means. The improved results failed to reach statistical
significance but trends were demonstrated. In both groups the improve-
ment in these characteristics was accompanied by relatively few serious
adverse reactions. Conclusion. Our preliminary data indicate that
i.v.CY is as effective (and relatively safe) compared to p.o.CY at
ameliorating the severer forms of lupus nephritis.
Preliminary results of a randomized therapeutic trial in patients with
mesangiocapillary glomerulonephritis. M.D. Pascoe and B.L. Rayner,
Renal Unit Groote Schuur Hospital, & Department of Medicine,
University of Cape Town, Cape Town, South Africa. Mesangiocapillary
glomerulonephritis (MCGN) is generally a severe giomerular disease,
with progression to end-stage renal failure occurring over S to 10 years.
Many attempts have been made to find a specific and effective treatment
for this disease, but no regimen has been consistently proven to be of
great benefit. The aim of this study was to compare the effect of aspirin
and dipyridamole (A&D) therapy with that of prednisolone and cyclo-
phosphamide (P&C) administered as bolus doses once every 3 months
over a period of 2 years. Patients with histologically proven MCGN,
with light, immune florescence and electron microscopic studies com-
patible with this diagnosis were entered into the study. Patients were
randomized to receive either aspirin 325 mg and dipyridamole 75 mg,
each 3 times daily, or prednisolone 7 mg/kg body weight daily for 3
consecutive days, and a single dose of 0.5 g/m2 body surface area of
cyclophosphamide, each administered once every 3 months for a total
of 2 years. Five patients commenced therapy in each group, one patient
in each group reached end-stage renal failure, between 6 and 12 months
after starting therapy. One patient in the A&D group was lost to
follow-up at 12 months with a plasma creatinine of 250 mol/liter. A
further patient in this group was withdrawn from treatment because of
side effects. One patient withdrew from the P&C arm for geographical
reasons after 3 courses of therapy, but was followed for 2 years. At the
start of therapy the plasma creatinine was 115.6 35.2 jmol/liter and
114.8 34.1 mol/liter, the ages 28.8 9 and 30.9 9 years, and the
U24pro excretion 5.85 and 4.2 g/day, and the Uprot/Uc. 0.34 and 0.69 g
prot/mmol creatinine in the P&C and A&D groups, respectively. Total
hemolytic complement, C3, circulating immune complexes and CRP
were similar in the 2 groups. During follow-up of those patients who did
not reach end-stage renal failure the urinary protein excretion remained
essentially unchanged, however, the plasma creatinine in the P&C
group did not increase and at 24 months the mean value was 100.5
13.1 .rmols/1iter while in the A&D group it was 229 28 mols/liter.
Conclusion. Although the number of patients in this study is too small to
draw firm or statistically valid conclusions it appears that treatment of
MCGN with P&C, may be of benefit in delaying the progression of this
disease, and that continuation of the study is warranted.
Is blood group P1 A significant protective factor in explaining why
hemolytic urmic syndrome (HUS) is less common in Black African
children? P.D. Thomson, K.E.C. Meyers, P.J. Nortman, and F.S.
Tolmay, Division of Paediatric Nephrology, University of Witwa-
tersrand and Johannesburg Hospital, and the S. African Blood Trans-
fusion Service, Johannesburg, Johannesburg, South Africa. We have
previously noted that HUS is uncommon in Blacks, as compared with
Caucasians, and HLA typing in HUS was not different to a group of
Caucasian controls. However, African Blacks have been shown to have
different HLA typing to Whites. That rural Blacks may be protected by
antibodies to the verocytotoxin is another possible factor. C.M. Taylor
et a! (Pediatr Nephrol 4:59—61, 1990) noted that there was an excess of
HUS patients with weak or absent expression of the erythrocyte P1
antigen (Pla). Verocytotoxin requires the terminal disaccharide of Pla
to bind to cells. This group postulated that P1 positivity may be
protective (toxin bound to erythrocytes, but the latter not damaged
because of not synthesizing protein), and P1 negativity a risk factor in
HUS (increased toxin bound to vulnerable nucleated endothelial cells).
We therefore investigated HUS patients (N = 28) for P1 status and
whether this affected renal function outcome if followed for at least 6
months, and groups of Black African (N = 38) and Caucasian (N = 41)
pediatric renal patients without HUS, and adult blood donors [Black (B)
N = 197, and Caucasian (C) N = 157]. Statistics are by the two-tailed
Fisher exact test.
Results HUS patient renal function outcome
Creatinine clearance <70 >70
mi/mm/i .73/rn2
P1
Antigen
Strongly pos.
1Weakly pos. or neg.
2
6*
(2 * transplanted)
15
5
P = 0.022
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They show the Birmingham trend of Pla p05. patients being less
severely affected as far as follow-up renal function is concerned.
Blood
donors
Ped. Non-
HUS renal
B C B C
P1
Antigen
1 Strongly pos.
Weakly pos. or neg.
151 94
46 63
P = 0.0001
33 22
5 19
P= 0.0013
In both the blood donors and non-HUS pediatric renal patients, the
Blacks have significantly greater Pla positivity, which may be a factor
in protecting them from HUS. This may occur with the erythrocyte
bound toxin being cleared in the reticulo-endothelial system. Other
possible factors, such as differing HLA antigens and verocytotoxin
antibodies, were not addressed in this study.
Congenital, infantile, familial and hereditary nephropathy. Eleven year
review at Baragwanath Hospital 1981—1991 inclusive. U.K Kala,
D. W. C. Jacobs, P.D. Thomson, K Meyers, and S. Verhaart, Depart-
ment of Paediatrics, Baragwanath Hospita4 University of the Witwa-
tersrand, Johannesburg, South Africa. The aim of this study was to
analyze congenital, infantile, familial and hereditary nephropathy, and
note any differences in histology and associated abnormalities, and
assess the outcome in terms of renal function and mortality. We studied
a retrospective analysis of congenital, infantile, familial and hereditary
nephropathy over the last eleven years presenting at Baragwanth
Hospital. Parameters which were assessed included: mode and age of
presentation, family history, presence of congenital infection, renal
histology, renal failure and mortality. A total of 48 children were
assessed, of which 47 were nephrotic and one had a nephritic picture.
The mean age of presentation was 18.4 months with a mortality of
39.6% (19). A total of 35.4% (17) had a family history or siblings with
nephrotic syndrome; 54.2% (26) presented in the first three months of
life; 6.2% (3) from 3 months to one year of life and 39.6% (19) were older
than one year but were either having a history of symptoms attributable
to the first year of life, a sibling presenting earlier or hereditary
nephropathy on renal histology. Renal histology was available in 75%
(36) of the patients and was very variable. Twelve not biopsied include
6 with proven congenital syphilis, 3 others had siblings with biopsy
proven Finnish nephrotic syndrome, one died before biopsy, one was
lost to follow-up and one is still to be biopsied. Seven of the 9 infants
with Finnish histology died mainly of infections and 2 were trans-
planted. One had mesangial sclerosis who died at the age of 4 months.
Three had membranous nephropathy, 2 of which had congenital infec-
tion and 1 was idiopathic. Fifteen infants had focal glomeruloscierosis
with two thirds of this group having hepatosplenomegaly. Three died in
this group and two went into renal failure. Five of these patients also
had pulmonary stenosis, one requiring balloon valvotomy. Three chil-
dren had Alport-like histology and electron microscopic findings. Three
children had nail patella syndrome, two of which went into renal failure,
one was transplanted and one died. Eight infants had congenital
infection, seven of which were syphilitic and one cytomegalovirus
infection. Three syphilitics died of septicemia. All 8 infants had
hepatosplenomegaly. Conclusion. Congenital infection is an important
cause of nephrotic syndrome in our context and must be excluded as
syphilis is easy to treat. Finnish nephrotic syndrome is invariably fatal.
Those infants having focal global sclerosis with mesangial proliferation
and hepatosplenomegaly exclude associated cardiac defects, especially
pulmonary stenosis.
The prevalence of antibodies to hepatitis C virus in two hemodialysis
units in the Western Cape. D. Jankelson, M. Becker, R. Moosa, and M.
Cassidy, Department of Medicine, University of Cape Town; and
Groote Schuur Hospital and Departments of Medicine and Virology,
University of Stellenbosch and Tygerberg, Cape Town, South Africa.
Hepatitis C virus is a major cause of parenterally transmitted non-A,
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non-B hepatitis. This study was undertaken to assess the prevalence of
antibodies to hepatitis C virus (HCV) in two hemodialysis units in the
Western Cape. In addition, the association of anti-HCV to sex, history
of blood transfusions, duration of dialysis, transplant status, liver
function tests and HB5Ag were recorded. Blood was taken from 103
hemodialysis patients attending Groote Schuur Hospital and Tygerberg
Hospital dialysis units. The mean age was 42.25 years (range 20—79) and
the ratio of males to females was 53 to 50. A second generation enzyme
linked immunosorbent assay (Elisa) was used to detect anti-HCV.
Twenty-four patients were anti-HCV positive giving a prevalence of
23.3%. The presence of anti-HCV was not related to sex. The anti-HCV
positive group had been on hemodialysis for a mean of 84.8 months
(range 3—192) compared to the 51.8 months (range 1—271) for the
anti-HCV negative group (P < 0.005). The mean number of blood
transfusions received by the anti-HCV positive group was significantly
higher than the anti-HCV negative group (29.6 vs. 14.0; P < 0.005).
More patients in the anti-HCV positive group had episodes of alanine
transaminase level twice the upper limit of normal (11/24 vs. 12/79; P <
0.05). In only one patient was this associated with a clinical episode of
hepatitis. None of these patients have abnormal ALT levels at present.
Nineteen (79.1%) of the anti-HCV positive patients had one or more
renal transplants in the past compared to 46 (58.2%) of the anti-HCV
negative group (P < 0.05). The 4 patients who were HBsAg positive
were all anti-HCV negative. In conclusion, HCV infection is common in
hemodialysis patients in these two dialysis units. Duration of dialysis,
blood transfusion and previous transplantation are risk factors in HCV
seroconversion. Using multivariant and logistic regression analysis,
however, the only independent predictor of the development of anti-
HCV positivity was duration of dialysis. All of the anti-HCV positive
patients are asymptomatic and have normal ALT levels at present,
although this does not exclude the possibility that some will develop
chronic liver disease in the future.
Renal tubular dysfunction in primary adenomatous hyperparathyroid-
ism. M.R. Nethononda, A.M. Meyers, and R.A. Botha, Departments of
Nephrology and Surgery, Johannesburg Hospital and University of
Witwatersrand, Johannesburg, South Africa. Certain components of
the Fanconi syndrome (FS) such as tubular bicarbonate and phosphate
loss occur in primary hyperparathyroidism (PHPT). The aim of this
study was to investigate the possibility of other components of the FS
occurring in patients with adenomatous PHPT and, if present, to assess
whether any clinical and biochemical features could predict the abnor-
malities. In addition, we wanted to assess whether parathyroidectomy
could reverse the tubular dysfunction. Five patients were prospectively
studied with particular note of age, sex, duration of symptoms, pres-
ence of renal calculi, nephrocalcinosis, calcium and phosphate levels,
presence of bone disease, size of the adenoma at surgery, GFR, renal
tubular acidosis (RTA) and the levels of 1,25(OH)2D3 and PTh. PTH
was measured as the intact molecule, 1,25(OH)2D3 via the thymus
receptor H3 RIA Kit method and quantitative 24-hour urinary amino
acids via the NIN Hydrin ionic exchange method. Gross generalized
aminoaciduria (AAuria) was found in patients no's 1 and 2 as shown in
the Table.
Patients
no.
Duration
symptoms
Renal
calculi
Size of
ademoma
AkI
phos
1
2
3
4
5
Years
Years
Months
Months
Months
+
+
+
+
+
2.5x3
3.5x3.5
1.5x1lxi
1.5x2
316
1,000
230
92
155
Patients
no.
GFR
mi/mm RTA
VITD
pg/mi
PTH
ng/liter
1
2
3
4
5
71
99
77
94
104
+
+
—
—
—
57
34
30
35
49
228
350
52
82
135
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No patient had radiological nephrocalcinosis. There was no difference
in Ca or phosphate between those with and without AAuria and no
patient had glycosuria. Serum uric acid was very low in those with
AAuria. From the Table it can be concluded that risk factors for
developing AAuria include duration if symptoms, size of adenoma,
height of PTH and severity of bone disease. Of note was that both the
generalized AAuna and the RTA normalized after parathyroidectomy.
We conclude that gross generalized reversible AAuria can occur in
PHPT and have postulated various risk factors. Although these 2 cases
are the first of this phenomenon to be reported in the literature, more
studies are required to confirm these findings and to investigate the
mechanisms involved.
The treatment of secondary hyperparathyroidism in chronic renal
failure with high dose pulse oral 1,25(OH)2D3. A. Pieterse, D. Britten, B.
Waite, and A.M. Meyers, Department of Nephrology, Johannesburg
Hospital, University of Witwatersrand, Johannesburg, South Africa.
The use of IVI 1 ,25(OH)2D3 has been well documented in the treatment
of secondary hyperparathyroidism in chronic renal failure. A single
recent study with the use of oral pulses of the vitamin was shown to
substantially reduce parathyroid hormone (PTH) levels in patients on
maintenance hemodialysis (HD). We have looked at this form of
therapy in a portion of our dialysis as well as chronic renal failure
patients, as a cost-effective and easily administered treatment for
secondary hyperparathyroidism and its related renal osteodystrophy.
Informed consent was obtained from 20 patients on HD (13 on hospital
and 7 on home HD units), at Johannesburg Hospital, all with secondary
hyperparathyroidism with PTH >200 ng/liter (intact molecule). All
patients were on calcium carbonate as phosphate binders and each was
commenced on 4 sg oral l,25(OH)2D3 administered twice weekly
immediately post dialysis. Baseline and monthly serum phosphate,
alkaline phosphatase and PTH, and weekly serum calcium levels were
monitored for 6 months. Patient's symptomatology before and on
therapy was carefully documented. In the event of side effects or
hypercalcemia, vitamin D dosages were reduced or temporarily stopped
until normocalcemia was attained. Usually vitamin D was then recom-
menced at a lower dose. One patient died from unrelated causes and
one withdrew from the study at month 4. We found a 43.9% reduction
in PTH levels in the 6 month period with a related 51.4% decrease in
alkaline phosphatase. The range of reduction of PTH levels was 9% to
96.6% with only one patient exhibiting an increase in PTH. Twelve out
of 20 patients had complete normalization of the PTH. An average
increase from 1.8 0.64 to 2.26 mmol/liter 0.53 was noted in
phosphate levels despite the use of phosphate binders. Serum calcium
levels were noted to increase from 2.13 0.24 to 2.4 mmoliliter 0.18,
6 of 20 patients developing hypercalcemia normalizing with reduction
and/or cessation of I ,25(OH)2D3. Side effects were noted to be mild and
self-limiting. From the above results it would appear that oral pulse
1 ,25(OH)2D3 is an effective therapy in hyperparathyroidism in patients
on dialysis, and being relatively cheap and easily administered with
minimal side effects, may play an important role in the treatment of this
condition, The anticipated hypercalcemia did not prove to be a major
problem. Further work and long-term follow-up of these patients is,
however, indicated.
Assessment of the adequacy of hemodialysis therapy. M.R. Moosa and
A. Fransman, Department of Internal Medicine, University of Stellen-
bosch, and Renal Unit, Tygerberg Hospital, Cape Town, South Africa.
Evaluating the adequacy of treatment delivered by hemodialysis re-
mains an enigma. A major advance in this respect was the urea kinetic
model of Sargent and Gotch on which the KT/V index is based. This
index is widely used to prescribe hemodialysis treatment. Dialysis
sufficient to maintain the KT/V index >1.0 was found in the National
Cooperative Study to correlate with a good outcome. We used this
index to assess the adequacy of the treatment that our patients on
hemodialysis were receiving. At the same time we sought to determine
how serious a problem blood recirculation was in the unit. All patients
on hemodialysis in our unit were invited to enter. Blood for serum urea
measurements were drawn at various intervals during a standard
hemodialysis. The KT/V index was calculated by the formula proposed
by Barth:
KT/V = (Upre — Upost)/Umid
where Upre is predialysis urea, U0 is end dialysis urea and Umid is urea
midpoint of dialysis. The percentage blood recirculation was calculated
using the formula:
(Cp — Ca)/(Cp — Cv) x 100
where Ca is the serum urea in the blood to the dialyzer, Cv in the blood
from the dialyzer and Cp in the peripheral blood. Fourty-seven patients
were studied, of whom 30 (63.8%) had a KT/V index of <1.0. Only 17
(36.1%) had an index >1.0. Of the males, 22(75.9%) had an index <1.0,
while 10 (55.6%) of the females had a value >1.0. Eleven (67%) of the
Black as opposed to 8 (57%) of the white patients had an index <1.0.
The recirculation of blood was well below 20% in all patients studied
bar one. Conclusions. The vast majority of the patients in our unit are
receiving less than adequate dialysis (as defined by a KT/V index >1.0).
The males have a greater tendency to be underdialyzed. Attempts to
improve the dialysis in our patients need to be undertaken and the
sequelae, if any, of inadequate dialysis need to be sought. Blood
recirculation is not a major problem in our unit.
Profunda femoris-saphenous PTFE graft—A method of vascular access
for hemodialysis. D. Manas, J.E. Jacobson, A.R. Pontin, and D. Kahn,
Department of Surgery, University of Cape Town, Cape Town, South
Africa. The simplest and probably the safest method for vascular access
for hemodialysis is the Cemino-Brescia arteriovenous fistula. An alter-
native site for the formation of a fistula is the antecubital fossa between
the brachial artery and the cephalic vein. Polytetrafluoroethylene
(PTFE) grafts are now used almost routinely in the arm for vascular
access, but unfortunately these grafts have a limited lifespan. Prosthetic
grafts in the leg for vascular access are hardly used because of the risks
and complications of sepsis. We describe a PTFE graft in the leg
between the profunda femoris artery and the saphenous vein which can
be used for vascular access for hemodialysis. The femoral vessels are
exposed through a 4 cm longitudinal incision below the inguinal
ligament. This reveals the femoral portion of the saphenous vein as it
enters the femoral vein, as well as the femoral artery with the origin of
the profunda femoris. A 6 mm VFFE graft is anastomosed end-to-end to
the profunda femoris artery after ligating the distal end. The graft is
tunneled in the subcutaneous tissue as far as middle of the thigh, and
then curved upwards by making a 1 cm incision. The tunneling process
is facilitated by using a Fr 9/12 bladder sound. The distal end of the graft
is then anastomosed end-to-end to the saphenous vein. The fistula thus
formed is ready for use in about two weeks. The flow is more than
adequate for dialysis. The advantage of this method of vascular access
is that if sepsis does supervene the removal of such a fistula would be
a simple procedure, since it would involve ligation of the profunda
femoris artery and the terminal portion of the saphenous vein. In
summary, a form of vascular access in the leg for hemodialysis for
patients who have run out of conventional sites is described.
Immunohistological analysis of cellular inifitrates in renal transplant
dysfunction. S. Naicker and R. Ramsaroop, Renal Unit, Addington
Hospital, University of Natal and Regional Laboratory Services,
Durban, South Africa. Since the introduction of cyclosporin A into
renal transplantation, the interpretation of renal biopsies has become
difficult. The interstitial infiltrate, once thought to be unmistakable
evidence of ongoing rejection, has been found in acute tubular necrosis,
cyclosporin nephrotoxicity and in grafts with stable function. It was not
possible to confirm or exclude the diagnosis of rejection in 27.5% of
cases in a study be Seron et al (Transplantation 1989). The aim of study
was to study the phenotypes of infiltrating cells in renal transplant
biopsies of patients with renal dysfunction. Twenty-three Tm-cut
needle biopsies of renal transplants were performed on 18 patients with
graft dysfunction. A minimum of 2 cores was obtained from each biopsy
and divided as follows: one specimen was frozen, a second put into
gluteraldehyde and the remaining tissue into Bouins fixative. B and T
cell staining (MTI-Clonab and MBZ-Clonab) was performed on the
paraffin processed tissue by the PAP method. Helper (T4-Dako) and
suppressor (T8-Dako) T cell staining was performed on the frozen tissue
also by the PAP method. Both methods used the Universal Mouse Kit,
with AEC as the chromogen. Seventeen biopsies were classified by light
microscopy as undergoing acute rejection, with 7 also showing features
of vascular rejection, 5 as interstitial nephritis and one as chronic
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rejection. Nine of the 10 biopsies with acute cellular rejection showed
predominantly increased T8 markers and 8 showed T3 staining. Of the
7 biopsies with acute vascular rejection, 6 showed increased B cells and
3 T8 cells; one biopsy did not show any immune markers. The single
biopsy with chronic rejection showed T3 and T8 markers. Four of the 5
biopsies with interstitial nephritis were positive for B cells and one for
T cells. Conclusion. The presence of activated and proliferating cells is
an important feature of rejection. While suppressor cells (T8) were
increased in acute cellular rejection, they were not consistently in-
creased in the more severe acute vascular rejection.
Malignancy in renal transplant recipients. L.P. Margolius, J.R.
Botha, A.M. Meyers, and J.A. Myburgh, Departments of Nephrology
and Surgery, Johannesburg Hospital, University of Witwatersrand,
Johannesburg, South Africa. Detailed records of 982 patients who had
received renal transplant grafts at the Johannesburg Hospital from 1966
until 1989 were retrospectively examined in order to assess the inci-
dence, spectrum, behavior and outcome of post-transplantation malig-
nancy. The incidence was 7.2%. The most common neoplasm, skin
carcinoma, accounted for 65% of tumors and occurred in 4.9% of those
transplanted. In squamous carcinoma cases, 72% of skin cancers were
recurrent, metastatic and lethal in 53%, 23% and 16% of instances,
respectively. It occurred virtually exclusively in Caucasians, 76.6
44.4 months post-transplant, and was 26-fold more than expected.
Non-cutaneous malignancies, 35% of tumors, occurred in 3.3% of
transplant recipients. Notably different from worldwide experience was
the finding of only three lymphomas, two presenting within one month
of transplantation. Kaposi's sarcoma, colorectal and bladder carcinoma
were the most common visceral malignancies. Patients with these
cancers were more likely to die of their neoplasms than were those with
skin malignancy (P < 0.001). There is an increasing prevalence of
malignancy with time, such that by 15 years 40% of those with
functioning grafts will have had cancer. The patient most likely to
develop a post-transplant malignancy will be male, will not have been
transfused prior to transplant (P < 0.00001), will have had a single (P <
0.01) cadaveric (P < 0.02) graft, and will have suffered few rejection
episodes. Cyclosporine gave rise to a greater number of lymphomas and
Kaposi's sarcomas but fewer skin cancers (P < 0.0001) than did
azathioprine. No patient with cancer prior to transplant developed a
recurrence, and no recipient receiving a graft from a donor dying of a
primary cerebral neoplasm developed cancer.
Nephrotic syndrome in children in Namibia 1975—1988: Clinical as-
pects. A.J. Van Buuren and W. Bates, Departments of Paediatrics and
Anatomical Pathology, University of Stellenbosch and Tygerberg Hos-
pital, Tygerberg, Cape Town, Republic of South Africa. Seventy Black
children with the nephrotic syndrome, from six ethnic groups in
Namibia, were evaluated at Tygerberg Hospital from 1975 to 1988.
Sixty-three were seen from 1980—1988 (average 7 per year); 45 children
were Ovambo (64.2%), 9 Damara (12.9%), 8 Kavango (11.4%), 4 Herero
(5.7%), 2 Nama (2.9%) and 2 Bushman. This ethnic distribution
approximately represents the ethnic populations in Namibia, the
Ovambo comprising 46.1% of the total population of I million.
Twenty-nine of the 70 children tested (41.4%) were found to be hepatitis
B carriers, 21 of whom were Ovambo. Three children from the
Tsumeb/Grootfontein area had positive serology for syphilis. Malaria
was not a factor. Age of the children varied between 1 year 10 months
and 15 years (average 7.2 years); 24% were under 5 years of age, 46%
were 5—10 years and 30% 10—15 years. There were 48 males (68.6%) and
22 females (31.4%). Of the 29 hepatitis B carriers 25 were males (86.2%)
and 4 females (13.8%). Their ages varied between 3 and 15 years
(average 6.6 years). Excluding the hepatitis B carriers, 23 were males
(56.1%) and 18 females (43.9%). Fifty-three children had hematuria, 20
were hypertensive and 13 were in chronic renal failure. Sixty-seven
renal biopsies and I post-mortem specimen were evaluated. One child
with a steroid resistant, relentless nephrotic syndrome died before a
biopsy could be done and 1 hepatitis B carrier, in end-stage renal
failure, was not biopsied. Of the 15 children with a mesangial prolifer-
ative glomerulonephntis, average age 7.3 years, 4 went into spontane-
ous biochemical remission, 10 were treated with steroids, 6 of whom
also required cytostatics. Six of the treated children remitted com-
pletely; 3 showed biochemical improvement and I did not respond. All
5 children with minimal change disease (MCD), average age 5.8 years,
received steroids, 2 of whom required cystostatics. Four remitted
completely but one died after 2 weeks on therapy. Seven of the 11
children with focal segmental glomerulosclerosis (FSGS), average age
9.1 years, were treated but only 2 showed complete or biochemical
remission, and one died of relentless nephrotic disease. Of the 13
children in chronic renal failure 2 had FSGS (1 hepatitis carrier), 2
mesangiocapillary GN (MCGN), 5 diffuse sclerosing GN and 4 hepatitis
B associated disease (2 MN, 1 MCGN and 1 unbiopsied). Eight children
are known to have died, 3 of a relentless nephrotic syndrome (1 MCD,
1 FSGS, I unbiopsied), I from penicillin anaphylaxis and 4 from
end-stage renal failure, 3 of whom were hepatitis B carriers. The pattern
of the nephrotic syndrome in Black Namibian children differs greatly
from the "Western" one. Minimal change disease is uncommon. MCD
and mesangial proliferative GN are potentially treatable and can only be
identified by biopsy; FSGS responds poorly to therapy. Hepatitis B is a
common associated factor with a significant male preponderance. All
but one case of membranous nephropathy were hepatitis B carriers; one
had endemic syphilis which responded well to penicillin.
Nephrotic syndrome in children in Namibia 1975—1988: Histological
classification. W. Bates and A.J. Van Buuren, Departments of Anatom-
ical Pathology and Paediatrics, University of Stellenbosch and Tyger-
berg Hospital, Tygerberg, Republic of South Africa. Seventy Black
children with nephrotic syndrome from Namibia were evaluated at
Tygerberg Hospital from 1975 to 1988. Sixty-seven biopsies were
performed and categorized essentially according to the WHO classifi-
cation of Churg. In one case of relentless nephrotic syndrome a
post-mortem diagnosis of focal segmental glomerulosclerosis was
made.
Type of nephrotic syndrome N
A. Minimal change 5
B. Focal segmental glomerulosclerosis II
C. Proliferative glomerulonephritis
1. (a) Mesangial proliferative glomerulonephritis
(b) Mesangial proliferative glomerulonephritis
with sclerosis
2. Endocapillary proliferative glomerulonephritis
3. Mesangiocapillary glomerulonephritis
14
1
I
3
D. Membranous nephropathy 27
E. Diffuse sclerosing glomerulonephritis 6
Total 68
Twenty-eight of the children biopsied were hepatitis BAg positive. The
morphological patterns seen in these biopsies were categorized as
membranous in 26 cases, with one case each of mesangiocapillary and
focal segmental glomeruloscierosis. Those classified as membranous
showed a range from a classical membranous pattern to a mixture of
membranous and mesangiocapillary with subepithelial deposits as well
as mesangial and subendothelial deposits with mesangial interposition.
The membranous group and the mesangiocapillary case were viewed as
hepatitis B-associated glomerular disease. The remaining membranous
example was associated with syphilis. Conclusion. The pattern of
nephrotic syndrome in Black children in Namibia differs markedly from
the Western one. It fits the Southern African pattern where membra-
nous disease, especially associated with hepatitis B, is found in up to
40% of Black children, predominantly boys.
Renotubular Fanconi syndrome with sensorineural deafness and pseu-
do-retinitis pigmentosa. A.J. van Buuren, M.M.B. van Rooyen, and S.f.
Engelbrecht, Departments of Paediatrics, Ophthalmology and Paedo-
audiology, Tygerberg Hospital and the University of Stellenbosch,
Cape Town, South Africa. Twelve White children (two groups of 6
each) from 9 families presented with a primary renotubular Fanconi
syndrome, progressive sensorineural deafness and "pseudo-retinitis
pigmentosa" with progressive loss of vision. Group A comprised six
children of normal intelligence, 2 boys and 4 girls (2 being sisters), from
5 families, presented to Tygerberg Hospital. There were 4 healthy sibs
in 3 of the families, The eldest boy's younger brother, with similar
symptoms, died at the age of 5½ years of sudden-onset renal failure. His
renal biopsy showed focal segmental glomerulosclerosis. There was no
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parental history of renal disease; urine dipstix and fundoscopy on the
parents was normal. No underlying systemic or metabolic disease, in
particular cystinosis, could be found, Chromosome studies were nor-
mal. All 6 children had a non-specific proteinuria, glycosuria, general-
ized aminoaciduria, hypouricemia and hypophosphatemia. Four had a
tendency to polyuria and 3 to metabolic acidosis and hypokalemia. Two
had hypercholesterolemia, one of whom developed a mild nephrotic
picture. Noted onset of renal disorder (metabolic bone disease) oc-
curred between 2 years 8 months and 9 years (mean 4.25 years). All
were growth retarded, 3 developed genu valgus deformities and one had
multiple fractures. Renal function is normal in 5 (present ages 7—18
years); one, aged 12, has early chronic renal failure. Renal biopsy in the
18-year-old boy was normal at 9½ years. Onset of loss of hearing
occurred between 2 and 6 years (mean 3.5 years). Five children
progressed to profound deafness (90 db loss) over 2—9 years. One
child had a 40 db loss at 6 years; she had a normal audiogram 8 months
earlier. One child had a successful cochlear implant, which may imply
that the deafness is due to degeneration of the neuroepithelial hair cells.
Onset of loss of vision occurred between 3 and 8 years (mean 5.75
years). Vision deteriorated to <6/60 in 3 children over 3—5 years, all of
whom later developed cataracts. One child has 6/40 vision after 3½
years and two have 6/24 vision after 1 year. Retinopathy tests showed
that all had pale optic discs and progressive pigment epithelial degen-
eration resulting in loss or absence of pigment; some had pigment
clumping and hyaloid bodies. Electroretinograms were markedly re-
duced in amplitude or extinct. Retinal changes were noted in 2 children
prior to onset of loss of vision. Group B comprised six children, 2 girls
and 4 boys (including 2 brother and sister pairs), with similar symptoms,
from 4 families were retrospectively evaluated. There were 8 healthy
sibs in 3 families (2 females from 1 family died at 3½ and 5 years from
a similar disease). Two had isolated hypercholesterolemia and 2 a
nephrotic syndrome. Two renal biopsies showed focal segmental gb-
merulosclerosis. All 6 had died between the age of 11 and 21½ years; 2
from sudden deterioration of renal function and 4 from unascertainable
causes. The renotubular Fanconi syndrome with sensorineural deafness
and "pseudo-retinitis pigmentosa" has not previously been docu-
mented, It is probably autosomal recessive with variable expression.
What clinical and histological parameters determine outcome in severe
acute renal allograft rejection? C.L. Edelstein and W. Bates, The Renal
Unit, Department of Internal Medicine and the Department of Ana-
tomical Pathology, University of Stellenbosch and Tygerberg Hospital,
Tygerberg, South Africa. Banfi has classified acute renal allograft
rejection histologically as follows: Grade 1 = mild, grade 2 = moderate,
grade 3 = severe and grade 4 = irreversible. The outcome of our
patients with severe rejection is variable. The aims of this study were to
determine what clinical and histological parameters determine outcome
in patients with severe acute renal allograft rejection. The clinical data
and renal biopsies of 33 patients with steroid-resistant acute rejection,
within 120 days of transplantation, were reviewed. The patients were
divided into two prognostic groups at 3 months post-biopsy: Group A(N = 20), poor outcome (creatinine greater than 800 mo1/liter or
permanently back on dialysis); and Group B (N = 13), favorable
outcome (recovery of renal function to a creatinine of less than 280).
Clinical parameters studied were age, pre-biopsy urine output and
creatinine, whether on dialysis at time of biopsy, HLA matches and
percentage sensitization to cytotoxic antibodies. Histological parame-
ters quantified in each biopsy were: glomerular necrosis, vessel
changes, lymphocytic infiltrate, interstitial hemorrhage, tubular damage
and parenchymal necrosis. Two patients had mild, 3 had moderate, 26
had severe and 2 had histologically irreversible rejection. None of the
clinical parameters differed significantly between prognostic groups A
and B. Patients with more than 10% glomerular necrosis had a signifi-
cantly poorer outcome (P = 0.02). Patients with any interstitial hemor-
rhage (P = 0.08) and vasculitis or severe vascular occlusion (P = 0.07)
tended to have a poorer outcome. Eleven patients received OKT3
monoclonal antibody therapy. Conclusions. Allograft function at the
time of severe rejection does not determine outcome. Severe acute
rejection episodes producing oliguria and requiring dialysis do not have
a significantly poorer outcome. A modification to the Banfi classifica-
tion of severe (grade 3) rejection is proposed to include a grade 3(a)
group with mild or moderate interstitial hemorrhage and a grade 3(b)
group with glomerular necrosis and severe interstitial hemorrhage
(involving more than 30% of the biopsy). The grade 3(b) group has a
significantly poorer outcome (P = 0.026). All 3 patients in the grade 3(a)
group who received OKT3 antibody therapy had a favorable outcome
compared to only 2 out of 8 in the grade 3(b) group.
The use of indapamide in patients with renal hypercalciuria. M.
Martins, A.M. Meyers, N. Whalley, and M. Sonnekus, Division of
Nephrology, University of the Witwatersrand and Johannesburg Hos-
pital, Johannesburg, South Africa. A large array of serious side effects,
such as the emergence of diabetes, hyperlipidemia, hyperuricemia,
hypokalemia, hypomagnesimia and postural hypotension, are a major
problem in patients given large doses (50—100 mg) of thiazides (T) to
normalize hypercalciuria. It is reported that Indapamide (I) in a dose of
2.5 mg daily produces no hypotension in normotensive individuals and
no other electrolyte, lipid or glucose disturbances. Pilot studies sug-
gested that the urinary Ca was reduced into the normal range. To
compare the present, accepted treatment, ('F), for hypercalciuria to I
with respect to efficacy and side effects, 8 patients with recurrent
calcium nephrolithiasis (RCN) and renal hypercalciuria (RH) were
tested. This is a preliminary report, the final aim being a minimum of
20—30 such patients. Thus meaningful statistics at present are difficult to
interpret. The trial was a double-blind crossover study. Twenty-four
hour urines and blood tests were done at the end of each phase and the
following parameters were estimated: Blood, standard renal function,
fasting glucose, HbA1C, lipid profile, Ca, Mg, uric acid; RBC, cation
concentration was measured using flame photometry and atomic ab-
sorption spectrophotometry; urine, usual stone work-up including Mg,
citrate and oxalate excretion.
Control Indapamide
Urine mmol/liter
Ca 6.12 2.62a 3.88 2.07a
Na 141 67.7a 151 40.9
Mg 3.25 1.37 2.89 1.28
Urate 1.34 1.05 0.96 1.16
Plasma mmol/liter
LDL 4.37 1.50 3.53 1.06
K 4.2 0.32a 3.71 0.33k
Gluc 6.0 1.7 6.5 1.75
HbA1C 7.5 2.43 8.0 1.99
Thiazide P value
Urine mmol/liter
Ca 4.34 2.42a <0.02
Na 186 llS,7a <0.04
Mg 3.63 1.60 NS
Urate 0.86 1.07 NS
Plasma mmol/liter
LDL 3.66 0.81 NS
K 3.9 0.28 <0.01
Glue 6.0 2.26 NS
HbA1C 7.6 2.21 <0.01
In conclusion, both drugs are equally effective with respect to lowering
the urinary Ca. T produced a significant natriuretic effect. Of note in the
urine is that I caused a decrease in Mg, and both drugs caused a
decrease in the urate levels (not significant). I produced a significant
hypokalemic effect, and it also caused a significant increase in HbA1C
levels (probably because the results of one diabetic patient have been
included), however, the mean is still within the normal range. No
significant changes were observed in other plasma or urine parameters.
No significant changes were seen in RBC electrolyte studies. The lack
of expected metabolic side effects in the T group cannot be explained,
but may either be due to insufficient numbers or to too short a period of
study.
Pulmonary nocardiosis in renal transplant recipients. P.A. Willcox and
CR. Swanepoel, Respiratory Clinic and Renal Unit, Department of
Medicine, Groote Schuur Hospital and University of Cape Town, Cape
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Town, South Africa. Nocardia is a relatively slow growing, gram-
positive, branching filamentous bacterium belonging to the order Acti-
nomycetales. Pulmonary infections are uncommon usually occurring in
immunocompromised patients. This study aimed to assess the clinical
presentation, diagnosis, treatment and outcome in renal transplant
recipients with this condition. The case records at Groote Schuur
Hospital between 1980 and 1991 were reviewed. Twenty-two patients
with pulmonary nocardiosis were diagnosed over this 12 year period.
Ten (45%) occurred in renal transplant recipients and of these 4 were
also diabetic. The average time from transplantation until infection was
6.5 months (range 1.7—12.5). Recent rejection episodes with intensifi-
cation of immunosuppression only occurred in one case. N. asteroides
was cultured in all cases except one where the species was not
identified. All patients presented with cough, usually with purulent
sputum, and one had a co-existing brain abscess. The chest radiograph
showed discrete nodules in 8 and consolidation in 2 patients. Cavitation
was present in 6 patients. Eight patients were treated with co-trimox-
azole, although in one patient this was changed to doxycycline and
amoxycillin and clavulonic acid following the development of leukope-
nia. One patient received sulphadiazine and another inappropriate
antibiotics. The duration of treatment ranged from 13 to 35 weeks with
a mean of 23 weeks. Two patients died, both from Nocardia infection.
Conclusions. Pulmonary nocardiosis is an uncommon infection in renal
transplant recipients at Groote Schuur Hospital. Patient response to
co-trimoxazole is usually good.
Mycobacterial infection in renal transplant recipients. C.M. Hall, P.A.
Wilcox, CR. Swanepoel, Renal Unit and Respiratory Clinic, Depart-
ment of Medicine, Groote Schuur Hospital and University of Cape
Town, Cape Town, South Africa, Infection is a common cause of
morbidity and mortality in renal transplant recipients. With the high
prevalence of tuberculosis in the Western Cape Province, mycobacte-
rial infection could be expected to be a significant problem in these
patients, but this has never been evaluated before. The aims of this
study were to determine the incidence, presentation and outcome in
graft function and patient survival of mycobacterial infection in renal
transplant recipients at Groote Schuur Hospital. We reviewed the case
records of all patients who underwent renal transplantation between
1980 and 1990. During this 11 year period, 674 patients underwent
transplantation, and of those 407 had remained in Cape Town and were
available for review. There were twenty-one cases of mycobacterial
infection (20 confirmed or presumed M. tuberculosis and 1 unidentified
MOrF). In 7 cases immunosuppression had been intensified within 3
months of diagnosis. The median time from transplantation to diagnosis
of mycobacterial infection was 15 months (range 2 to 74). Chest
radiograph findings included consolidation (13), miliary pattern (4),
pleural effusion (3), tuberculoma (2), cavitation and hilar lymphadenop-
athy (1 each). Diagnosis of tuberculosis was made on positive sputum
smears in 7, pleural biopsy in 2, fine needle aspiration biopsy in 1 and
fibreoptic bronchoscopy in 10 patients (brushings 8, transbronchial
biopsy 3). Extrapulmonary tuberculosis (in addition to pulmonary
tuberculosis) occurred in 5 patients (tuberculous meningitis 1, renal
tuberculosis I and disseminated infection 4). All patients received 3
anti-tuberculous drugs, including rifampicin and isoniazid, for between
6 and 18 months. At the end of' the review period 11(52%) patients were
alive, 9 with functioning grafts and 2 on dialysis. Four patients died
while receiving anti-tuberculous treatment, but death was only directly
related to tuberculosis. Tuberculosis is an important infection in renal
transplant recipients in Cape Town. Disseminated disease is less
common than is reported elsewhere.
Urological problems in 162 pediatric renal transplant patients. K.E.C.
Meyers, P.D. Thomson, and P.G. Beale, Division of Paediatric Neph-
rology, Department of Paediatrics & Paediatric Surgery, University of
the Witwatersrand and Johannesburg Hospital, Johannesburg, South
Africa. The aim of this study was to describe and delineate the
urological problems in our children post-transplantation. A retrospec-
tive analysis of all the children transplanted to date in our unit was
performed. Statistics were given as means, standard deviations, Stu-
dent's t-tests and the Fisher exact test. All tests were two-tailed, with
a P value set at <0.05 for significance. Of 162 transplant patients, 8.6%
(14) experienced urological problems. Of these 11 were male and 3
female (4.44:1). Patient ages ranged from 1.78 to 16.25 years (10.6
4.4); 11 had cadaver and three living-related transplants, 12 were first
and 2 second transplants. Four (28%) had pre-transplant urological
problems: two primary reflux and two posterior urethral valves. Clinical
suspicion, usually of obstruction, led to the diagnosis in all patients. In
prediagnosis, 93% showed a rise in the creatinine level. The most useful
radiological investigations in making the diagnosis were renal ultra-
sound (11/14), DTPA or IVP (9/14). Voiding cystourethrogram and
prograde nephrograms were each done in 2 patients, and computerized
abdominal tomography and abdominal X-ray in 1 each. The urological
problems defined were: distal ureteric obstruction (DUO) 11/14
(78.5%), urethral stricture 3/14, lymphocele 1/14, and bladder calculus
1/14 (2 patients had 2 problems each). Of the 80 patients with an
antireflux procedure, 9 (11.25%) developed DUO, whereas only 1 of 39
patients with no antirefiux surgery had DUO (2.6%), P = 0.2. Presen-
tation of DUO was from 1 week to 156 weeks post-transplantation (95%
CI 6.75 to 73.4 weeks). Of the 11 with DUO 4 had biopsy proven
rejection. Graft survival in the rejection versus nonrejection DUO
groups were 0.76 0.26 years vs. 5.2 2.7 years (P = 0.0046). All
grafts in the rejection group compared to one in the nonrejection DUO
group have failed (P = 0.03). Of the 5 failed grafts with DUO, 4/4 that
had rejection also had recurrent pre- and post-transplant UTI's (P =
0.03). CONCLUSIONS. Risk factors for DUO in pediatric transplant
patients include: proven rejection episodes, recurrent UTI's and antire-
flux ureteric anastomosis. Suggestions for the management and preven-
tion of DUO as the major urological problem in our pediatric renal
transplants are: all patients need a biopsy to assess the extent of
rejection; vigorous urinary antisepsis in susceptable patients; and
routine ureteroneocystostomy without antireflux procedures.
The pediatric transplantation compliance study continued. K.E.C.
Meyers, P.D. Thomson, and H. Weiland, Division of Paediatric Neph-
rology, University of the Witwatersrand and Johannesburg Hospital,
Johannesburg, South Africa. The aim of this study was to assess the
observed compliance, knowledge and attitudes of the patients and
parents currently attending the pediatric transplantation follow-up
clinic. A questionnaire designed to evaluate general characteristics,
confirm compliance, explore attitudes and knowledge was administered
to 56 transplant (TP) patients and their parents. Patients have previ-
ously been divided into noncompliant (NC), doubtful (D) and compliant
(C) groups based on: (i) admission of not taking medication, (ii) admit
medication had finished, (iii) missed clinic visit such that medication
would have been insufficient, or (iv) confirmed by retrospective CsA
analysis. Fifty-six current TP attenders were assessed: C 33, D 11, and
NC 12 pts. Ages were: C 13.4 3.8 years; NC 12 5.0 years were
similar. There were more NC males (C 20/33, NC 11/12), P = 0.0352.
The average number of TP's was C 1.25 0.44, NC 1.58 0.79, P <
0.05 for 3rd T/P. NC pts missed their clinic appointments, C (6%) vs.
NC (50%), P = 0.0026 and forgot to take their medicines; C (21%) vs.
NC (50%), P < 0.05, more often than C pts. Of the medications, 9%
were troubled by side effects; 25% said there was poor labeling, and
30% that poor explanations were given by the dispensary. Of medica-
tions being taken: (i) actual No. C 7.5 2.0, D 9.6 2.5, NC 10.0 3.0,
the (ii) number remembered C 7 2.0, D 8 3.5, NC 8 3.5; and (iii)
name remembered by pt. C 6.5 2.5, D 7.5 3.0, NC 4.0 3.5. For
ii vs. iii C vs. NC, P = 0.00001 (one way analysis of variance). The
number of medications not known expressed as (i — u/i) x 100, C 7.5
18%, NC 21.8 25%; P = 0.02; 17% didn't fully understand medication
instructions, and 13% found the medications confusing. For Knowl-
edge; C 72% vs. NC 20% correctly identified their immunosuppres-
sives, P = 0.0057; 14% said they could stop their immunosuppressives;
40% didn't know alternative drug names; only 41% knew their original
illness; C 54.5% vs. NC 8.3%, P = 0.0198, and only 45.5% knew why
they needed a TP; 85% would like more ongoing teaching post-TP.
Conclusions. The major areas in pediatric TP pts needing intervention
have been identified. A pre-transpiant compliance contract, education
strategies, medication checks and an ongoing surveillance program are
planned.
Blood eosinophilia as an early predictor of acute cellular rejection in
post-renal transplantation children. P.D. Thomson and K.E.C. Meyers,
Division of Paediatric Nephrology, University of the Witwatersrand
and Johannesburg Hospital, Johannesburg, South Africa. Previous
workers have discussed the association of blood eosinophilia with acute
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cellular rejection in renal transplantation. We compared various param-
eters retrospectively in 16 pediatric renal transplant recipients (age
range: 6—15 years; mean 9 years), who had had a biopsy-proven acute
cellular rejection (Group A) with 20 (age range l—l5 years; mean 10
years), who did not have an obvious clinical rejection in the first month
post-transplant (Group B). Both groups received transplants over the
last 6 years, and other patients whose early courses were compounded
by acute tubular necrosis, cyclosporin A toxicity or obstructive urop-
athy were not considered. One half of Group A was prepared for
transplantation with total lymphoid irradiation (A: TLI-l-), whereas only
4 of Group B were. Statistics used were all two-tailed; Fisher exact and
Student's t.
Means sr Group A
Blood Post-transplant:
Eosinophil Day 4
Count Day 8
Tender Kidney
Temperature >38°C
When eosinophils increased:
a) C of ESR 50% above baseline
b) Creatinine clearance mI/mm/i .73 m2
282 311.0
466 517.9
8/16
10/16
9/14
64 23.1
Means SD Group B P value
Blood Post-transplant:
Eosinophil Day 4
Count Day 8
Tender Kidney
Temperature >38°C
When eosinophils increased:
a) of ESR 50% above baseline
b) Creatinine clearance mI/mini
1.73 in2
90.9 125.7
116.8 142,4
1/20
1/19
2/15
84 22.5
0.038
0.018
0.0058
0.0008
0.0 13
0.0083
Groups A and B were not significantly different when comparing
hypertension, decreased urine output, and when eosinophils increased
with the actual ESR, CRP, cyclosporin A and prednisilone dosages.
Group A (biopsy confirmed rejections) were further defined as: days
post-transplant when clinical diagnosis made = 10.8 6.8, biopsy
confirmed = 12.7 7.5, of eosinophils of >200/mi3 above baseline =
5.5 2.3, (13/16) all in days post-transplant, and eosinophils t prior to
diagnosis 2.8 2.1 days. The creatinine clearance when eosinophils
were 64 23.1 vs. creatinine clearance when diagnosis of rejection
confirmed = 37.1 12.8 ml/minll.73 m2 (P = 0.0007). The TLI
prepared group vs. standard therapy (cyclosporine, prednisilone +
occasional azathioprine), were not significantly different for the above
parameters, but the dosages of cyclosporin A (TLI+: 6.3 1.0;
non-TLI: 9.7 3.8 mg/kg/day; (P = 0.0418) and prednisilone (TLI+:
1.2 0.5; non-TLI 2.3 1.1 mg/kg/day; P = 0.0255) were. Conclusion.
An increase in blood eosinophils frequently antedates a biopsy-con-
firmed acute cellular rejection, and together with a tender kidney, an
increase in temperature and an increase of the ESR of 50% above
baseline, suggests that an acute cellular rejection is beginning. This can
lead to an earlier diagnosis and treatment to prevent too great a fall in
the creatinine clearance. The eosinophil count was not significantly
affected by TLI preparation, but the dosages of cyclosporin A and
prednisilone were lower in this group.
Long-term results with conversion from cyclosporine to azathioprine 3
months after renal transplantation. D. Kahn, D. Manas, A.R. Pontin,
C.R. Swanepoel, M.J.D. Cassidy, Renal Transplant Unit, Groote
Schuur Hospital, Cape Town, South Africa. The impact of cyclosporine
on the results after solid organ transplantation has been extensively
documented. When cyclosporine was first introduced, controversy
existed as to how it should best be administered. We originally adopted
a policy of converting patients from cyclosporine to azathioprine at
three months after the renal transplant. In this study we report the
long-term results with such a protocol. All patients who underwent
renal transplantation between January 1983 and December 1986 were
included in the study. All patients received comparable intra- and
post-operative care. In particular, the immunosuppression protocol
consisted of cyclosporine and steroids. Cyclosporine 4—S mg/kg was
started intra-operatively and administered intravenously over the first
24 hours. Oral cyclosporine 10 mg/kg in two divided doses was
commenced on the first post-operative day and dose was adjusted,
according to the whole blood levels, to achieve a trough level of 400—bOO
ng/ml. The patients also received methyl prednisolone 24 mg daily. At
three months post-operatively all patients were converted to azathio-
prine (1—2 mg/kg) and methyl prednisolone, and the cyclosporine
stopped after an overlap of one week. The dose of oral methyl
prednisolone was increased from 24 mg to 32 mg and then reduced by
2 mg monthly. Rejection episodes were treated with bolus intravenous
doses of methyl prednisolone 500 mg per day for 4 days. During the
study period 238 patients were subjected to renal transplantation. There
were 153 males and 85 females with a mean age of 35 years (range 9—59
years). There were 165 patients of mixed race origin, 58 were White and
15 were Black. Kidneys from cadaver donors were used for 200
transplants and from a living related donor in 38 patients. Forty-seven
of the 200 cadaver transplants were re-transplants. All patients were
followed for at least 4 years. The actual graft survival in living-related
transplants was 95% and 92% at 1 and 4 years, respectively. The actual
graft survival for recipients of first cadaver kidneys was 82% and 67%
at 1 and 4 years, respectively (P < 0.01). After re-transplantation the
graft survival at I and 4 years was 64% and 45%, respectively. In
conclusion, the long-term results of converting from cyclosporine to
azathioprine at 3 months after renal transplantation compare favorably
with other immunosuppression protocols. However, in this study we
were unable to assess the side-effects related to long-term steroid usage.
Changing patterns of post-renal transplant peptic ulcer disease and
implications with respect to treatment. L.M. Fingleson, J.R. Botha, L.P.
Margolius, A.M. Meyers, and J.A. Myburgh, Renal Transplant Unit,
University of the Witwaiersrand, Johannesburg, Republic of South
Africa. Peptic ulceration occurs more frequently with more serious
consequences in renal transplant patients. Late atypical presentation
due to immunosuppression results in increased mortality in especially
complicated disease. This has resulted in aggressive surgical prophylac-
tic and management protocols. The aim of this study was to compare
current patterns of disease presentation with those of the precyclospo-
rine era and the implications thereof with respect to the aggressive
surgical management protocols applied currently. A retrospective anal-
ysis of 1142 adult renal transplant records from 1967—1990 was under-
taken. A total of 648 of these were treated with cyclosporine. In
comparing the groups prior to and after the introduction of cyclospo-
rine, no significant change in incidence was demonstrated (4.56% vs.
4.23%). However, fewer (25.9% vs. 65.2%) presented with complica-
tions, the presentation was later (55.6% vs. 43.5% later than 6 months),
with lowered mortality rate (7.4% vs. 26.1%) in the post-cyclosporine
group. Despite the aggressive surgical protocol, 70.4% of ulcers post-
cyclosporine were inadvertently treated conservatively (80% of those
with uncomplicated and 42.9% with complicated disease). Follow-up
was for a mean of 878 days with no complications on therapy and no
deaths. The overall mortality for complicated disease was high (36.4%)
with little difference between the two groups. Conclusions. The pattern
of peptic ulcer disease in the post-cyclosporine era has changed in that
the presentation is later, with fewer complications and lower mortality.
The data cast some doubt on the current aggressive surgical policy
especially when applied to uncomplicated disease.
